Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction.
Uebleis C, Hellweger S, Laubender RP, Becker A, Sohn HY, Lehner S, Haug A, Bartenstein P, Cumming P, Van Kriekinge SD, Slomka PJ, Hacker M. Uebleis C, et al. Among authors: laubender rp. Int J Cardiovasc Imaging. 2013 Oct;29(7):1645-53. doi: 10.1007/s10554-013-0254-2. Epub 2013 Jun 7. Int J Cardiovasc Imaging. 2013. PMID: 23744128
Early repolarization pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years.
Siebermair J, Sinner MF, Beckmann BM, Laubender RP, Martens E, Sattler S, Fichtner S, Estner HL, Kääb S, Wakili R. Siebermair J, et al. Among authors: laubender rp. Europace. 2016 May;18(5):718-25. doi: 10.1093/europace/euv301. Epub 2016 Jan 11. Europace. 2016. PMID: 26759124
Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy.
Uebleis C, Hellweger S, Laubender RP, Becker A, Sohn HY, Lehner S, Haug A, Bartenstein P, Cumming P, Van Kriekinge SD, Slomka PJ, Hacker M. Uebleis C, et al. Among authors: laubender rp. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1561-9. doi: 10.1007/s00259-012-2157-1. Epub 2012 Jul 3. Eur J Nucl Med Mol Imaging. 2012. PMID: 22752450
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. Modest DP, et al. Among authors: laubender rp. Int J Cancer. 2012 Aug 15;131(4):980-6. doi: 10.1002/ijc.26467. Epub 2011 Nov 17. Int J Cancer. 2012. PMID: 21960311 Free article. Clinical Trial.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V. Boeck S, et al. Among authors: laubender rp. Br J Cancer. 2013 Feb 5;108(2):469-76. doi: 10.1038/bjc.2012.495. Epub 2012 Nov 20. Br J Cancer. 2013. PMID: 23169292 Free PMC article. Clinical Trial.
97 results